bioAffinity Technologies, Inc.

BIAF

bioAffinity Technologies, Inc.

BIAF

Insider Sentiment (TTM):

Last Purchase:2022-09-01Last Sale:-Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:242,202Shares Outstanding:4,494,752Institutional Ownership Pct.:5.39%

Earnings Market Reaction:

Filing Date:2026-05-11Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Services-Commercial Physical & Biological Research

IQV INCY MEDP CRL ABSI NRC

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Cash And Cash Equivalents At Carrying Value	3	6	8	1	0	1	1	1	2	3	5	8
Accounts And Other Receivables Net Current	1	1	0	0	1	1	1	2	1	1	1	0
Assets Current
Assets Current	4	8	9	2	2	3	3	3	4	4	6	9
Inventory Net	0	0	0	0	0	0	0	0	0	0	0	0
Prepaid Expense And Other Assets Current	0	1	0	0	0	0	0	0	0	0	0	0
Assets Noncurrent
Property Plant And Equipment Net	0	0	0	0	0	0	0	0	0	0	1	0
Operating Lease Right Of Use Asset	1	0	0	0	0	0	0	0	0	0	0	-
Finance Lease Right Of Use Asset	1	1	0	0	1	1	1	1	1	1	-	-
Goodwill	1	1	1	1	1	1	1	1	1	1	1	-
Intangible Assets Net Excluding Goodwill	1	1	1	1	1	1	1	1	1	1	1	-
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets	8	11	12	5	6	7	7	7	8	8	10	9
Liabilities And Stockhold…
Accounts Payable Current	1	1	1	1	1	1	1	1	0	1	1	0
Accrued Liabilities Current	2	2	1	1	1	1	1	1	1	1	1	1
Deferred Revenue Current	0	0	0	0	0	0	0	0	0	0	0	0
Loans Payable Current	-	-	-	-	-	-	-	-	-	-	-	0
Liabilities Current
Liabilities Current	3	3	2	3	3	3	2	2	2	2	2	1
Operating Lease Liability Current	0	0	0	0	0	0	0	0	0	0	0	-
Finance Lease Liability Current	0	0	0	0	0	0	0	0	0	0	0	-
Notes Payable Current	0	0	0	0	0	0	0	0	0	-	-	-
Liabilities Noncurrent
Operating Lease Liability Noncurrent	1	0	0	0	0	0	0	0	0	0	0	-
Finance Lease Liability Noncurrent	1	1	0	0	0	0	1	1	1	1	1	-
Long Term Notes Payable	0	0	0	0	0	0	0	0	0	-	-	-
Liabilities	4	4	3	7	4	4	3	3	3	3	3	1
Preferred Stock Value	0	0	0	-	-	-	-	-	-	-	-	-
Common Stock Value	0	0	0	6	0	0	0	0	0	0	0	0
Stockholders Equity
Stockholders Equity	4	7	9	-2	1	3	3	3	5	5	7	8
Additional Paid In Capital	76	76	74	58	58	56	54	52	52	49	49	48
Retained Earnings Accumulated Deficit	-72	-69	-65	-60	-56	-54	-51	-49	-47	-45	-42	-40
Liabilities And Stockholders Equity	8	11	12	5	6	7	7	7	8	8	10	9
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	-	0.001	0.001	0.001	0.001	-	0.001	0.001
Preferred Stock Shares Authorized	20	20	20	20	-	20	20	20	20	-	20	20
Preferred Stock Shares Issued	0	0	0	-	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	-	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.007	0.01	0.007	0.007	0.007	0.01	0.007	0.007	0.007	0.007	0.007	0.007
Common Stock Shares Authorized	350	350	350	400	400	350	400	400	400	400	400	457
Common Stock Shares Issued	4	4	3	4	4	0	1	0	0	0	0	0
Shares Outstanding	4	4	3	4	4	0	1	0	0	0	0	0

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-12.18%	-57.87%	-	-	-	-	-	-	-	-	-	-
2025	37.86%	32.04%	42.72%	-6.27%	-65.88%	-67.97%	-11.41%	-33.70%	-38.04%	75.39%	6.28%	-9.42%
2024	22.34%	20.74%	-7.98%	-25.84%	2.25%	-23.03%	-21.80%	-29.32%	-42.86%	91.92%	0.77%	-9.23%
2023	11.54%	-0.55%	-1.65%	-4.86%	-32.97%	-23.62%	-2.15%	6.18%	9.65%	13.40%	27.75%	-15.79%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 50+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	1.36	2.60	3.65	0.64	0.55	0.87	1.02	1.15	2.22	1.77	3.07	11.17
Quick Ratio	1.19	2.41	3.44	0.47	0.41	0.72	0.84	1.03	2.02	1.62	2.87	10.80
Working Capital	1.16M	4.66M	6.25M	-919.48K	-1.55M	-409.81K	57.97K	354.14K	2.16M	1.72M	4.05M	7.88M
Leverage & Debt
Debt to Equity	1.17	0.51	0.30	-3.22	2.85	1.50	1.10	0.94	0.53	0.69	0.46	0.10
Interest Coverage TTM	-265.14	-238.27	-184.25	-138.57	-114.15	-96.82	-90.01	-108.50	-141.66	-214.77	-5.26	-2.90
Debt Ratio	0.54	0.34	0.23	1.45	0.74	0.60	0.52	0.48	0.35	0.41	0.31	0.09
Efficiency & Turnover
Asset Turnover TTM	0.84	0.71	0.75	1.35	1.30	1.27	1.12	0.94	0.53	0.25	0.03	0.00
Per Share Metrics
Diluted EPS TTM	-3.53	-2.89	-2.30	-1.87	-1.57	-1.30	-1.19	-1.25	-1.03	-0.89	-0.99	-1.31
Free Cash Flow Per Share TTM	-2.43	-1.82	-1.33	-1.24	-1.07	-1.06	-1.03	-1.02	-0.85	-0.68	-0.65	-0.80
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	-	-	-	-	-	-	-	-	99.45%	98.00%	76.35%	92.98%
Operating Profit Margin TTM	-204.29%	-171.58%	-153.20%	-131.01%	-109.38%	-95.64%	-89.13%	-118.51%	-169.31%	-314.84%	-2,684.58%	-28,856.25%
Net Profit Margin TTM	-280.57%	-241.96%	-217.50%	-152.18%	-110.55%	-96.56%	-90.16%	-119.41%	-169.42%	-313.41%	-2,725.72%	-44,878.94%
Growth Metrics
Net Revenue Growth (1Y)	-35.75%	-34.18%	-27.66%	4.99%	78.40%	269.68%	2,802.08%	28,632.55%	-	-	-	-
Net Income Growth (1Y)	63.06%	64.93%	74.51%	33.80%	16.40%	13.89%	-4.01%	-23.55%	-	-	-	-
EPS Growth (1Y)	125.63%	122.29%	93.92%	49.53%	52.15%	46.73%	20.34%	-4.67%	-	-	-	-
Valuation Metrics
P/E TTM	-1.08	-0.41	-1.28	-4.62	-4.98	-21.02	-52.53	-51.95	-58.89	-49.84	-35.37	-41.95
P/B TTM	4.70	0.84	2.13	-25.26	33.70	73.01	142.15	132.19	93.71	81.48	44.50	59.20
P/S TTM	3.04	0.99	2.79	7.02	5.51	20.29	47.36	62.03	99.77	156.22	964.16	18,828.42
Market Cap	17.21M	6.09M	18.94M	53.95M	48.51M	189.97M	443.64M	453.82M	492.64M	395.62M	311.23M	479.41M
Enterprise Value	14.81M	461.57K	11.57M	53.41M	48.96M	189.90M	444.11M	454.07M	491.33M	394.00M	308.01M	471.17M
Calculated Values
Free Cash Flow TTM	-10.94M	-9.40M	-8.51M	-7.75M	-6.65M	-7.34M	-7.30M	-7.11M	-6.91M	-6.09M	-5.76M	-7.00M
Net Debt	-2.40M	-5.63M	-7.36M	-540.15K	447.70K	-73.69K	462.97K	247.39K	-1.31M	-1.62M	-3.22M	-8.24M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2022-09-01Purchase

Owner: Edwards, James Michael

Title: Chief Financial Officer

Shares: 2,448

Price/Share: -

Value: -

Shares Owned: 30,323

Relationship: Officer

Ownership: Direct

2022-08-31Purchase

Owner: Knight, Peter S

Title: -

Shares: 8,163

Price/Share: -

Value: -

Shares Owned: 22,448

Relationship: Director

Ownership: Direct

2022-08-31Purchase

Owner: Zannes, Maria

Title: President, CEO

Shares: 16,326

Price/Share: -

Value: -

Shares Owned: 19,897

Relationship: Director,Officer

Ownership: Direct

2022-08-31Purchase

Owner: Anderson, Robert A.

Title: -

Shares: 4,081

Price/Share: -

Value: -

Shares Owned: 4,081

Relationship: Director

Ownership: Direct

2022-08-31Purchase

Owner: Diamond, Stuart

Title: -

Shares: 4,081

Price/Share: -

Value: -

Shares Owned: 4,081

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2022-09-01	Edwards, James Michael	Officer	Chief Financial Officer	Direct	Purchase	2,448	-	-	30,323	4
2022-08-31	Knight, Peter S	Director	-	Direct	Purchase	8,163	-	-	22,448	4
2022-08-31	Zannes, Maria	Director,Officer	President, CEO	Direct	Purchase	16,326	-	-	19,897	4
2022-08-31	Anderson, Robert A.	Director	-	Direct	Purchase	4,081	-	-	4,081	4
2022-08-31	Diamond, Stuart	Director	-	Direct	Purchase	4,081	-	-	4,081	4
2022-08-31	Girgenti, Steven	Director,Officer	Executive Chairman	Direct	Purchase	40,916	-	-	861,099	4
2022-08-31	Harvey, Sandler Revocable…	Director,TenPercentOwner	-	Indirect	Purchase	16,326	-	-	1,584,144	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

5.39%

Inst. Shares: 242,202

Shares Outstanding: 4,494,752

2025-12-31

1.52%

Inst. Shares: 78,422

Shares Outstanding: 5,163,246

2025-09-30

4.29%

Inst. Shares: 274,232

Shares Outstanding: 6,398,100

2025-06-30

5.78%

Inst. Shares: 362,316

Shares Outstanding: 6,266,490

2025-03-31

7.88%

Inst. Shares: 490,248

Shares Outstanding: 6,219,392

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	242,202	4,494,752	5.39%
2025-12-31	78,422	5,163,246	1.52%
2025-09-30	274,232	6,398,100	4.29%
2025-06-30	362,316	6,266,490	5.78%
2025-03-31	490,248	6,219,392	7.88%
2024-12-31	535,651	6,958,701	7.70%
2024-09-30	457,690	7,109,681	6.44%
2024-06-30	399,694	7,003,363	5.71%
2024-03-31	197,127	8,129,418	2.42%
2023-12-31	156,043	8,964,838	1.74%
2023-09-30	119,176	8,912,617	1.34%
2023-06-30	96,694	8,732,409	1.11%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

bioAffinity Technologies, Inc. (BIAF) — SEC Financial Statements & Analysis

bioAffinity Technologies, Inc. (BIAF) is a services-commercial physical & biological research company, incorporated in DE. bioAffinity Technologies, Inc. trades on BIAFW: Nasdaq as: BIAF: Nasdaq. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), bioAffinity Technologies, Inc. reported a -35.75% year-over-year revenue growth, a Gross Profit Margin of 99.45% (TTM), a Debt-to-Equity ratio of 1.17x, a Price-to-Sales (P/S) ratio of 3.04x (TTM), a Price-to-Book (P/B) ratio of 4.7 (TTM), at a market cap of $17.21M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -35.75%
Gross Profit Margin TTM: 99.45%
Debt To Equity: 1.17x
P/S TTM: 3.04x
P/B TTM: 4.7
Market Cap: $17.21M

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is bioAffinity Technologies, Inc. in?

bioAffinity Technologies, Inc. (BIAF) operates in the Services-Commercial Physical & Biological Research industry.

What is BIAF's market cap?

bioAffinity Technologies, Inc. (BIAF) has a market capitalization of $17.21M as of 2026-03-31.

What exchange does BIAF trade on?

bioAffinity Technologies, Inc. (BIAF) trades on the BIAFW: Nasdaq.

Where is bioAffinity Technologies, Inc. incorporated?

bioAffinity Technologies, Inc. is incorporated in DE.

bioAffinity Technologies, Inc. (BIAF) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.